title: Chlamydia pneumoniae antibody response in patients with acute myocardial infarction and their follow-up.
abstract: METHODS
  This study concerned the possible relations between seroreactivity to Chlamydia pneumoniae and myocardial infarction. A group of 29 patients with acute myocardial infarction (AMI), 74 members of a healthy control group, and a subgroup of 24 members of a healthy control group matched for age, sex, and coronary risk factors (HCM) were included in the study. In addition, we evaluated the AMI group in a 1-year patients' follow-up study. We used two different tests to detect anti-C. pneumoniae antibodies: recombinant enzyme immunoassay antilipopolysaccharide antibodies and a reference microimmunofluorescence test.
  
  
  RESULTS
  High titers of C. pneumoniae microimmunofluorescence antibodies were found in 89.65% of the AMI group and in 25% of the HCM group (p = 0.0000065). Immunoglobulin A-microimmunofluorescence was 51.72% in the AMI group and 20.83% in the HCM group (p = 0.0042). Immunoglobulin G and immunoglobulin A antilipopolysoccharide titers were 65.51% and 62.60% in the AMI group and 20.83% in the HCM group, respectively (p = 0.006). High concentrations of interleukin-6 were found in 86.20% of our AMI group (p value = 54.38 pg/ml) when compared with the control group. A good correlation between interleukin-6 levels and immunoglobulin A-lipopolysaccharide titers (r = 0.658) was found.
  
  
  CONCLUSIONS
  The presence of a high prevalence rate and high titers of immunoglobulin G and immunoglobulin A-specific anti-C. pneumoniae antibodies in AMI at admission demonstrated the presence of a specific anti-C. pneumoniae immunization in the AMI population.
authors.affiliation: Sexually Transmitted Diseases Centre, Infectious Diseases Unit, S.M. Annunziata Hospital, Florence, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Mazzoli
authors.forename: N
authors.initials: N
authors.lastname: Tofani
authors.forename: A
authors.initials: A
authors.lastname: Fantini
authors.forename: F
authors.initials: F
authors.lastname: Semplici
authors.forename: F
authors.initials: F
authors.lastname: Bandini
authors.forename: A
authors.initials: A
authors.lastname: Salvi
authors.forename: R
authors.initials: R
authors.lastname: Vergassola
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000914:Antibodies, Viral / Q000097:blood*; D016022:Case-Control Studies; D016993:Chlamydophila pneumoniae / Q000276:immunology*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005455:Fluorescent Antibody Technique; D005500:Follow-Up Studies; D006801:Humans; D007070:Immunoglobulin A / Q000097:blood; D007074:Immunoglobulin G / Q000097:blood; D015850:Interleukin-6 / Q000097:blood; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000276:immunology / Q000382:microbiology*; D015995:Prevalence; D012307:Risk Factors
chemical_list: D000914:Antibodies, Viral; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D015850:Interleukin-6